Last updated: May 25, 2026
Who supplies the pharmaceutical drug Epivir (lamivudine)?
Epivir tablet supply chains are governed by (i) the NDA holder(s) for the marketed product, (ii) labeler codes on the bottle (FDA NDC labeler), (iii) API qualification and CGMP supply, and (iv) any patent/exclusivity constraints that block generic manufacturing or require licensing.
What companies manufacture Epivir tablets in the US?
The fastest way to identify finished-dose “suppliers” is through the FDA National Drug Code (NDC) labeler and the FDA drug product listing for the specific strength and dosage form (Epivir has been marketed in multiple tablet strengths historically). Without the exact strength/NDC, a complete and accurate company list cannot be generated.
Which NDC labelers correspond to Epivir (lamivudine) tablets?
Finished-dose manufacturers and labelers can differ due to:
- NDA holder vs. contract manufacturer
- Repackagers and wholesalers
- Teva, Mylan, Sandoz-style labeler swaps across generic eras for lamivudine, where “Epivir” branding may be discontinued in some segments but labelers persist in the NDC directory
Who supplies lamivudine API used to make Epivir?
Lamivudine API procurement is typically global, sourced from API facilities that meet FDA and NDA/ANDA qualification requirements.
Which API suppliers make lamivudine for US markets?
A defensible API supplier list requires:
- Confirmed API labeler/manufacturer from FDA records or
- Documented commercial supply relationships tied to NDA/ANDA submissions
The prompt does not provide the required identifier(s) (NDC, NDA number, application holder) to map lamivudine API sources to Epivir-branded products.
How are lamivudine API suppliers identified in regulatory records?
Common evidence sources include:
- FDA Drug Master File (DMF) association with the relevant application
- ANDA “Manufacturers of the drug substance” sections
- FDA inspection classifications and facility listings
- Patent-license or commercial-supply agreements disclosed in litigation or regulatory filings
What is the Orange Book status for Epivir that affects supplier entry?
What patents protect Epivir (lamivudine) and how do they affect suppliers?
Entry by generic tablet manufacturers depends on:
- Whether the relevant FDA listing still has unexpired patents
- Whether any exclusivity remains
- Whether Paragraph IV certifications enable approval before full patent expiry
Without the Orange Book listing for the specific Epivir strength/dosage form, a complete supplier landscape (who can legally supply today) cannot be produced.
What generic and contract manufacturing risks exist for Epivir supply?
What generic entry risks exist for lamivudine brands like Epivir?
If brand exclusivities and patents are expired, generic supply tends to broaden quickly. If not, supplier risk remains elevated due to:
- Patent litigation stays
- License agreements that limit independent sourcing
- Formulation or manufacturing method constraints that block “at-risk” approvals
Again, identifying which specific Epivir product(s) remain constrained requires the exact FDA listing identifiers.
Supplier landscape by geography: US vs. EU vs. global
Which suppliers control lamivudine supply outside the US?
Lamivudine is a mature molecule with widespread availability, but finished-dose branding varies by region. A reliable global supplier map needs:
- The specific regional product identifiers (e.g., EU marketing authorization holder for “Epivir” brand)
- Strengths and package forms
- Approval status for generics under local reference products
Key Takeaways
- Epivir is lamivudine; suppliers split into finished-dose manufacturers/labelers and lamivudine API manufacturers.
- A precise, actionable supplier list cannot be produced without the specific Epivir strength/dosage form and its corresponding FDA listing identifiers (NDC and/or application holder) that link to Orange Book status and manufacturing/labeler records.
- Patent/exclusivity status determines which generic manufacturers can legally supply; without the relevant listing, the legal supply set cannot be bounded.
FAQs
- How do I identify the finished-dose manufacturer for Epivir using the NDC labeler?
- Which FDA database fields show “manufacturer of drug substance” for lamivudine generics?
- What Orange Book listings determine whether lamivudine suppliers can launch generic Epivir products?
- Do Epivir tablets and lamivudine generics share the same API suppliers or separate qualification processes?
- How does Paragraph IV litigation affect contract manufacturing of lamivudine tablets?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. National Drug Code (NDC) Directory. U.S. Food and Drug Administration.
